If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
==== Russian preparations and invasion of Georgia ==== The commission noted, "the sum of actions undertaken by Russia by mid-2008 amounted to a threat of force vis-à-vis Georgia", and that Georgia felt "a substantial risk of Russian military intervention". The commission noted that "Russian military operations in Georgia in August 2008 appear to most analysts to have been well-planned and well-executed." The commission noted that many international experts "also believe that the massive Russian military action in August 2008 caught the Georgians off guard and unprepared both strategically and tactically." The commission noted that Russian military base Ugardanta in the Dzau District and Russian military rehabilitation centre in the north-west Tskhinvali were constructed before the August 2008 conflict. As far as legality of use of force by Russia was concerned, the report took a "differentiated" approach, dividing "the Russian reaction to the Georgian attack" into two phases – the one, which was "the immediate reaction in order to defend Russian peacekeepers" in Tskhinvali and the second one, "the invasion of Georgia by Russian armed forces reaching far beyond the administrative boundary of South Ossetia", which was "beyond the reasonable limits of defence".
Myiasis is prevalent in livestock, and especially in domestic sheep. Myiasis in sheep is often caused by blowflies (Lucilia sericata and L. cuprina in particular) and is commonly referred to as blowfly strike. Blowfly strike, and other flystrike, occurs worldwide but is most common in regions where hot and wet conditions are sustained, such as Sub-Saharan Africa, Southeast Asia, Latin America, Australia, and New Zealand. As of 2021, blowfly strike accounts for over A$280 million a year in losses for the Australian sheep industry. As mitigation, Australian sheep farmers may engage in mulesing, a procedure designed to remove strips of wool-producing skin that are the most common targets for flies. Farmers may also dock lambs' tails to reduce the likelihood of infestation. However, both mulesing and tail-docking have received criticism from animal welfare groups, who say the mitigative procedures are excessive and can have other negative effects. In addition to blowfly strike in sheep, myiasis from screwworm flies (Cochliomyia hominivorax in particular) regularly cause upwards of US$100 million in annual damages to domestic cows and goats. Screwworm-related myiasis is primarily mitigated through the sterile insect technique.
Organoleptic examination or sensory analysis is the most basic form of investigation for textiles. This can include visible damage as well as smells that indicate pollutants, humidity, and decomposition of organic materials. Sampling should be used minimally to help with the inspection of fibers. Sampling requires the extraction of a small amount of the material. Inspection of fibers can include Fourier transform infrared (FTIR), Raman, and attenuated total reflectance (ATR) spectroscopy, “When sampling a work of art is deemed appropriate, scientists routinely use scanning electron microscopy–energy dispersive spectroscopy (SEM-EDS), X-ray diffraction (XRD), and Fourier transform infrared spectroscopy (FTIR).” (ATR): attenuated total reflectance is a sampling technique used in conjunction with infrared spectroscopy which enables samples to be examined directly in the solid or liquid state without further preparation. This process is ideal for optically dense materials. (FTIR): Fourier transform infrared spectroscopy is a technique used to obtain an infrared spectrum of absorption or emission of a solid, liquid or gas. An FTIR spectrometer simultaneously collects high-resolution spectral data over a wide spectral range. This process requires computer processing to convert raw data into usable results related to wavelengths that indicate how materials absorb or emit infrared light.
The Rosalind Franklin Covid Laboratory in Leamington Spa, the UK's first COVID-19 testing mega lab which opened in June 2021, is put up for sale by the UK government. 10 November Data from the Office for National Statistics shows the UK economy did not grow between July and September 2023. Chancellor Jeremy Hunt blames high interest rates for the situation, but says that overall the economy has performed better than expected during 2023. Downing Street says that Rishi Sunak still has "full confidence" in Home Secretary Suella Braverman, while Chancellor Jeremy Hunt says her comments "are not words that I myself would have used". The High Court rules that Prince Harry and six others can go ahead with a case against Associated Newspapers Ltd for unlawfully obtaining information about them. Associated Newspapers had wanted to stop the case arguing the time on the claims had expired. The Metropolitan Police imposes an exclusion zone around the Cenotaph ahead of planned demonstrations over Remembrance Weekend. 11 November A pro-Palestinian march through central London goes ahead as planned, attended by an estimated 300,000 people, who walk from Park Lane down to the U.S. Embassy in Nine Elms. Police arrest more than 100 counter-protesters. Deepfake audio of London Mayor Sadiq Khan calling for Armistice Day to be rescheduled for the march is reportedly circulated by a far-right group. The Met Police says it "does not constitute a criminal offence".
==== Protein chips ==== Balancing the use of mass spectrometers in proteomics and in medicine is the use of protein micro arrays. The aim behind protein micro arrays is to print thousands of protein detecting features for the interrogation of biological samples. Antibody arrays are an example in which a host of different antibodies are arrayed to detect their respective antigens from a sample of human blood. Another approach is the arraying of multiple protein types for the study of properties like protein-DNA, protein-protein and protein-ligand interactions. Ideally, the functional proteomic arrays would contain the entire complement of the proteins of a given organism. The first version of such arrays consisted of 5000 purified proteins from yeast deposited onto glass microscopic slides. Despite the success of the first chip, it was a greater challenge for protein arrays to be implemented. Proteins are inherently much more difficult to work with than DNA. They have a broad dynamic range, are less stable than DNA and their structure is difficult to preserve on glass slides, though they are essential for most assays. The global ICAT technology has striking advantages over protein chip technologies.
Sources: en.wikipedia.org
=== Dose reconstruction using biological dosimetry === Since about 1988, in addition to physical dosimetry, biological dosimetry has made it possible to reconstruct the individual dose of ionizing radiation. This is especially important for unforeseen and accidental exposures, where radiation exposures occur without physical dose monitoring. Biological markers, particularly cytogenetic markers in blood lymphocytes, are used for this purpose. Techniques for detecting radiation damage include analyzing dicentric chromosomes after acute radiation exposure. Dicentric chromosomes result from defective repair of chromosome breaks in two chromosomes, resulting in two centromeres instead of one like undamaged chromosomes. Symmetric translocations, detected through fluorescence in situ hybridization (FISH), are used after chronic or long-term exposure to radiation. The micronucleus test and the premature chromosome condensation (PCC) test are available to measure acute exposure.
=== Function === ACTH released from the corticotropes binds to G protein-coupled receptors in the adrenal cortex, where it stimulates the production of glucocorticoids (primarily cortisol). ACTH binds to the melanocortin 2 receptor and, through signal transduction, increases levels of cholesterol esterase, the transport of cholesterol across the mitochondrial membrane, cholesterol binding to P450SCC and, an increase in pregnenolone synthesis. It also serves as a secondary stimulus for the synthesis of mineralocorticoids such as aldosterone, which serve an important role in regulating the salt balance of the blood. Glucocorticoids released by the adrenal cortex inhibit production of CRH and ACTH, forming a negative feedback loop.
Relatively high doses of SSRIs are needed for effectiveness in the treatment of OCD. Studies have found that high dosages of SSRIs above the normally recommended maximums are significantly more effective in OCD treatment than lower dosages (e.g., 250 to 400 mg/day sertraline versus 200 mg/day sertraline). In addition, the combination of clomipramine and SSRIs has also been found to be significantly more effective in alleviating OCD symptoms, and clomipramine is commonly used to augment SSRIs for this reason. Studies have found that intravenous clomipramine, which is associated with very high circulating concentrations of the drug and a much higher ratio of clomipramine to its metabolite desmethylclomipramine, is more effective than oral clomipramine in the treatment of OCD. There is a case report of complete remission from OCD for approximately one month following a massive overdose of fluoxetine, an SSRI with a uniquely long duration of action. Taken together, stronger serotonin reuptake inhibition has consistently been associated with greater alleviation of OCD symptoms, and since clomipramine, at the clinical dosages in which it is employed, is effectively the strongest SRI used medically (see table above), this may underlie its unique effectiveness in the treatment of OCD. In addition to serotonin reuptake inhibition, clomipramine is also a mild but clinically significant antagonist of the dopamine D1, D2, and D3 receptors at high concentrations.
== Location == Using radioimmunoassay and immunocytochemistry, endomorphins have been localized within the nervous systems of humans, mice, rats, and monkeys. Both endomorphin tetrapeptides are abundant in the human neocortex. Endomorphin-1 can be found in the hypothalamus and thalamus of the diencephalon, and in the striatum and lateral septum of the telencephalon. In the hindbrain, endomorphin-1-reactive neurons are more abundant than are those immunoreactive for endomorphin-2. Endomorphin-2 is predominantly found in the spinal cord, specifically in presynaptic terminals of afferent neurons in the dorsal horn region. It has been found co-localized with calcitonin and with the pain-conveying neurotransmitter, substance P. Neither endomorphin-1 nor endomorphin-2 has been identified in the amygdala or the hippocampus.
Sources: en.wikipedia.org
=== Carl Hardee Sr. campaign === In March 2017, Hardee's began to move away from the sexualized ads by releasing a commercial featuring a white bearded character played by Charles Esten as "Carl Hardee Sr." who had come back into the office (much to the delight of the employees) to find his son (Drew Tarver), a.k.a. "Carl Jr." who was focusing on sex appeal over its food. The commercial marked a turning point in CKE's advertising, as the company wanted to move away from its provocative ads and focus more on food and as a competitor to Five Guys, Steak 'n Shake, and In-N-Out Burger. "Carl Hardee Sr." was also expected to become the new company spokesperson.
=== Electrophile === Vinyl halides are common coupling partners in the Stille reaction, and reactions of this type are found in numerous natural product total syntheses. Normally, vinyl iodides and bromides are used. Vinyl chlorides are insufficiently reactive toward oxidative addition to Pd(0). Iodides are normally preferred: they will typically react faster and under milder conditions than will bromides. This difference is demonstrated below by the selective coupling of a vinyl iodide in the presence of a vinyl bromide.
The bacterial outer membrane is found in gram-negative bacteria. Gram-negative bacteria form two lipid bilayers in their cell envelopes - an inner membrane (IM) that encapsulates the cytoplasm, and an outer membrane (OM) that encapsulates the periplasm. The composition of the outer membrane is distinct from that of the inner cytoplasmic cell membrane - among other things, the outer leaflet of the outer membrane of many gram-negative bacteria includes a complex lipopolysaccharide whose lipid portion acts as an endotoxin - and in some bacteria such as E. coli it is linked to the cell's peptidoglycan by Braun's lipoprotein. Porins can be found in this layer.
Np(IV) or Np4+ is pale yellow-green in acidic solutions, where it exists as hydrated complexes (Np(H2O)4+n). It is quite unstable to hydrolysis in acidic aqueous solutions at pH 1 and above, forming NpOH3+. In basic solutions, Np4+ tends to hydrolyze to form the neutral neptunium(IV) hydroxide (Np(OH)4) and neptunium(IV) oxide (NpO2). Neptunium(V)
Exenatide augments pancreas response (i.e. increases insulin secretion) in response to eating meals; the result is the release of a higher, more appropriate amount of insulin that helps lower the rise in blood sugar from eating. Once blood sugar levels decrease closer to normal values, the pancreas response to produce insulin is reduced; other drugs (like injectable insulin) are effective at lowering blood sugar, but can "overshoot" their target and cause blood sugar to become too low, resulting in the dangerous condition of hypoglycemia. Exenatide also suppresses pancreatic release of glucagon in response to eating, which helps stop the liver from overproducing sugar when it is unneeded, which prevents hyperglycemia (high blood sugar levels). Exenatide helps slow down gastric emptying and thus decreases the rate at which meal-derived glucose appears in the bloodstream. Exenatide has a subtle yet prolonged effect to reduce appetite, promote satiety via hypothalamic receptors (different receptors than for amylin). Most people using exenatide slowly lose weight, and generally the greatest weight loss is achieved by people who are the most overweight at the beginning of exenatide therapy. Clinical trials have demonstrated the weight reducing effect continues at the same rate through 2.25 years of continued use. When separated into weight loss quartiles, the highest 25% experience substantial weight loss, and the lowest 25% experience no loss or small weight gain. Exenatide reduces liver fat content.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.